Urinary estrogen metabolites and prostate cancer : a case-control study and meta-analysis
Barba, Maddalena, Yang, Li, Ph.D., Schünemann, Holger J., Sperati, Francesca, Grioni, Sara, Stranges, Saverio, Westerlind, Kim C., Blandino, Giovanni, Gallucci, M. (Michele), Lauria, Rossella, Malorni, Luca and Muti, Paola. (2009) Urinary estrogen metabolites and prostate cancer : a case-control study and meta-analysis. Journal of Experimental and Clinical Cancer Research, Vol.28 (Article 135). ISSN 1756-9966
WRAP_Stranges_Urinary.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under License Creative Commons Attribution.
Official URL: http://dx.doi.org/10.1186/1756-9966-28-135
Objective: To investigate prostate cancer (Pca) risk in relation to estrogen metabolism, expressed as urinary 2-hydroxyestrone (2-OHE1), 16α-hydroxyestrone (16α-OHE1) and 2-OHE1 to 16α-OHE1 ratio.
Methods: We conducted a case-control study within the Western New York Health Cohort Study (WNYHCS) from 1996 to 2001. From January 2003 through September 2004, we completed the re-call and follow-up of 1092 cohort participants. Cases (n = 26) and controls (n = 110) were matched on age, race and recruitment period according to a 1:4 ratio. We used the unconditional logistic regression to compute crude and adjusted odds ratios (OR) and 95% confident interval (CI) of Pca in relation to 2-OHE1, 16αOHE1 and 2-OHE1 to 16α-OHE1 by tertiles of urine concentrations (stored in a biorepository for an average of 4 years). We identified age, race, education and body mass index as covariates. We also conducted a systematic review of the literature which revealed no additional studies, but we pooled the results from this study with those from a previously conducted case-control study using the DerSimonian-Laird random effects method.
Results: We observed a non-significant risk reduction in the highest tertile of 2-OHE1 (OR 0.72, 95% CI 0.25-2.10). Conversely, the odds in the highest tertile of 16α-OHE1 showed a non-significant risk increase (OR 1.76 95% CI 0.62-4.98). There was a suggestion of reduced Pca risk for men in the highest tertile of 2-OHE1 to 16α-OHE1 ratio (OR 0.56, 95% CI 0.19-1.68). The pooled estimates confirmed the association between an increased Pca risk and higher urinary levels of 16α-OHE1 (third vs. first tertile: OR 1.82, 95% CI 1.09-3.05) and the protective effect of a higher 2-OHE 1 to 16α-OHE1 ratio (third vs. first tertile: OR 0.53, 95% CI 0.31-0.90).
Conclusion: Our study and the pooled results provide evidence for a differential role of the estrogen hydroxylation pathway in Pca development and encourage further study.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Q Science > QP Physiology
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Prostate -- Cancer -- Research, Cancer -- Endocrine aspects, Estrogen -- Physiological effect, Hydroxylation|
|Journal or Publication Title:||Journal of Experimental and Clinical Cancer Research|
|Publisher:||BioMed Central Ltd.|
|Official Date:||8 October 2009|
|Access rights to Published version:||Open Access|
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics,
Actions (login required)